HBI0101 CART

Phase 2Cell therapy

PPolina Stepensky

HBI0101 CART is one of 50 biologic programs targeting Autoimmune Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseRecruiting

Multiple Myeloma, RefractoryRecruiting

Autoimmune DiseasePhase 1

Recruiting

Multiple Myeloma, RefractoryPhase 2

Recruiting

Competition

Competitive Landscape

70 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Atgam

Novartis

Phase 2

2 2

Cytosar

Teva

Phase 2

1 3

Rayos

RRoxane Laboratories

Phase 2

2 4

Alkeran

AApotex Inc.

Phase 2

1 5

Vepesid

AAvyxa

Phase 2

1 6

Bicnu

MMelissa K Accordino

Phase 2

1 7

Fludara

Sanofi

Phase 1

6 8

Rituxan

Roche

Phase 1

2 9

CAR-T Cell

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

3 10

Cytoxan

BBaxter Healthcare Corporation

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Multiple Myeloma, Refractory

NCT06971380

Q4 2030

Phase 1Recruiting

Autoimmune Disease

NCT07085676

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Recruiting·PPolina Stepensky·Phase 1·NCT07085676·60 enrolled

Multiple Myeloma, Refractory1 trial

A Phase 2 Trial to Study Efficacy and Safety of HBI0101 (NXC-201) CART in Subjects With Multiple Myeloma and Light-Chain Amyloidosis.

Recruiting·PPolina Stepensky·Phase 2·NCT06971380·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HBI0101 CART. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HBI0101 CART compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HBI0101 CART. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Polina Stepensky company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: PPolina Stepensky

HBI0101 CART

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Q4 2030

Trials by Indication[1]

Autoimmune Disease1 trial

Multiple Myeloma, Refractory1 trial

References

Drug Info

Quick Facts

Related News